Erste Asset Management GmbH Sells 53,000 Shares of Amicus Therapeutics, Inc. $FOLD

Erste Asset Management GmbH lowered its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 45.4% during the third quarter, Holdings Channel reports. The firm owned 63,850 shares of the biopharmaceutical company’s stock after selling 53,000 shares during the period. Erste Asset Management GmbH’s holdings in Amicus Therapeutics were worth $507,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of FOLD. Osaic Holdings Inc. grew its stake in Amicus Therapeutics by 450.1% during the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 3,358 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Amicus Therapeutics by 472.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 3,677 shares in the last quarter. Strs Ohio bought a new stake in shares of Amicus Therapeutics during the 1st quarter worth approximately $30,000. ANTIPODES PARTNERS Ltd bought a new position in Amicus Therapeutics in the third quarter valued at approximately $31,000. Finally, Versant Capital Management Inc grew its stake in shares of Amicus Therapeutics by 499.1% during the third quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 4,387 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Citigroup reissued a “neutral” rating and set a $14.50 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Monday, December 22nd. Zacks Research cut shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 26th. Leerink Partners downgraded Amicus Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $17.00 to $14.50 in a research note on Monday, December 29th. Needham & Company LLC downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 19th. Finally, Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Amicus Therapeutics has an average rating of “Hold” and an average target price of $15.39.

Insider Buying and Selling at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 77,926 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $10.86, for a total transaction of $846,276.36. Following the sale, the chief executive officer directly owned 1,129,782 shares in the company, valued at approximately $12,269,432.52. The trade was a 6.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider David Michael Clark sold 25,643 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $11.00, for a total value of $282,073.00. Following the sale, the insider directly owned 271,332 shares in the company, valued at $2,984,652. This trade represents a 8.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 204,211 shares of company stock valued at $2,564,947. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Stock Performance

Shares of FOLD stock opened at $14.37 on Monday. The stock has a market capitalization of $4.51 billion, a P/E ratio of -179.63 and a beta of 0.43. The company has a current ratio of 2.84, a quick ratio of 1.88 and a debt-to-equity ratio of 1.43. The firm’s 50 day moving average is $14.29 and its 200 day moving average is $10.71. Amicus Therapeutics, Inc. has a 12 month low of $5.51 and a 12 month high of $14.38.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The business had revenue of $185.21 million during the quarter, compared to analysts’ expectations of $185.00 million. During the same quarter in the prior year, the firm posted $0.09 earnings per share. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. On average, sell-side analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.